Skip to main content
Neuland Laboratories Limited. logo

Neuland Laboratories Limited. — Investor Relations & Filings

Ticker · NEULANDLAB ISIN · INE794A01010 LEI · 335800AVHZURTYQ17N08 BSE.NS Manufacturing
Open in API
Filings indexed 943 across all filing types
Latest filing 2026-05-12 Regulatory Filings
Country IN India
Listing BSE.NS NEULANDLAB

About Neuland Laboratories Limited.

https://www.neulandlabs.com

Neuland Laboratories Limited specializes in the development and manufacture of Active Pharmaceutical Ingredients (APIs) and provides comprehensive Custom Manufacturing Solutions (CMS). The company focuses on complex chemistry and high-quality standards, operating state-of-the-art manufacturing facilities that comply with international regulatory requirements, including those of the USFDA and EDQM. Its product portfolio spans diverse therapeutic areas such as cardiovascular, central nervous system, anti-infectives, and antiasthmatics. Neuland supports pharmaceutical companies globally through the entire lifecycle of a drug, from early-stage clinical development to commercial-scale production. By leveraging advanced technical expertise and a robust quality management system, the organization delivers reliable chemical synthesis and process optimization services to both innovator and generic drug manufacturers.

Recent filings

Filing Released Lang Actions
Recommendation of final dividend for the financial year 2025-26
Regulatory Filings Classification · 74% confidence The document is a formal SEBI‐compliant “Outcome of Board Meeting” announcement to BSE/NSE under Regulation 30/33, summarizing (i) approval of audited financial results for the year ended March 31, 2026, (ii) recommendation of a final dividend, (iii) director appointment, AGM date/record date and a capacity expansion. It references enclosed audited results and auditor’s report but does not itself contain a standalone annual report, earnings presentation, or Excel data file. This is a general regulatory disclosure rather than the report itself, so it falls under the catch‐all Regulatory Filings category (RNS).
2026-05-12 English
42nd Annual General Meeting of the Shareholders of the Company is scheduled to be held on Tuesday, August 4, 2026
Regulatory Filings Classification · 65% confidence The document is a stock‐exchange filing under SEBI Listing Regulations describing the outcome of a board meeting – approval of audited annual financial results, dividend recommendation, director appointment, AGM notice and record date – and includes the independent auditor’s report. It is not the full annual report (10‐K) itself, nor a simple earnings release (ER) or standalone audit report (AR). It also covers board appointments (MANG) but is broader. Therefore it falls under general regulatory/stock exchange filings (RNS) as a fallback.
2026-05-12 English
Updates
Board/Management Information Classification · 85% confidence The document is a formal SEBI Listing Regulation disclosure titled “Outcome of Board Meeting” filed with BSE and NSE. It reports Board approval of audited annual financial results under Regulation 33, recommends a final dividend, appoints an additional director, fixes the AGM date and record date, and details capacity enhancement. This is an event disclosure of Board/Management decisions rather than the full Annual Report itself. Therefore it best fits the Board/Management Information category (MANG).
2026-05-12 English
The Record Date for the Purpose of Determining the Shareholder Eligible to receive the final dividend for the financial year ended March 31, 2026, has been fixed as July 24, 2026
Board/Management Information Classification · 82% confidence The document is an official filing to stock exchanges under SEBI Listing Regulations announcing the outcome of a Board Meeting, including approval of audited annual financial results, declaration of final dividend, appointment of an additional director, AGM date, record date, and capacity expansion. This is not the full Annual Report itself nor merely a report publication notice; it is a Board/Management Information announcement. Therefore, the most appropriate category is MANG (Board/Management Information).
2026-05-12 English
Record Date
Earnings Release Classification · 88% confidence The document is an official Outcome of Board Meeting under SEBI Listing Regulations disclosing Audited Financial Results (Standalone & Consolidated) for the year ended March 31, 2026, along with the Statutory Auditors’ Report, dividend recommendation, director appointment, and AGM details. It is not a full Annual Report but rather the formal announcement of annual financial results—matching the definition of an Earnings Release. FY 2026
2026-05-12 English
General Updates
Regulatory Filings Classification · 85% confidence The document is an official SEBI Listing Regulations disclosure filed with BSE and NSE titled “Outcome of Board Meeting,” summarizing the board’s approval of audited financial results, auditor’s report, final dividend recommendation, director appointment, AGM date, record date, and capacity expansion. It is a regulatory exchange announcement rather than a full annual report or interim/quarterly report and does not fit more specific categories. Therefore, it falls under the general Regulatory Filings category.
2026-05-12 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.